GSK Gelecekteki Büyüme

Future kriter kontrolleri 4/6

GSK kazanç ve gelirin sırasıyla yıllık 21.9% ve 3.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 21.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 28.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

21.9%

Kazanç büyüme oranı

21.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.6%
Gelir büyüme oranı	3.8%
Gelecekteki özkaynak getirisi	28.7%
Analist kapsamı	Good
Son güncelleme	26 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BMV:GSK N - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	34,308	6,520	6,489	9,537	16
12/31/2025	32,391	5,834	5,615	8,369	17
12/31/2024	31,226	3,802	3,962	6,542	17
9/30/2024	31,311	2,511	4,917	7,421	N/A
6/30/2024	31,446	4,033	5,222	7,479	N/A
3/31/2024	30,740	4,484	5,330	7,673	N/A
12/31/2023	30,328	4,928	4,436	6,768	N/A
9/30/2023	29,652	6,078	3,247	5,477	N/A
6/30/2023	29,334	5,373	2,486	4,586	N/A
3/31/2023	29,085	4,455	2,892	4,914	N/A
12/31/2022	29,324	4,461	5,341	7,403	N/A
9/30/2022	29,024	3,387	7,620	9,265	N/A
6/30/2022	27,822	3,505	8,073	10,506	N/A
3/31/2022	26,731	4,013	7,611	10,163	N/A
12/31/2021	24,696	3,316	5,939	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	24,354	4,873	6,839	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	N/A	6,991	N/A
3/31/2018	30,024	1,035	N/A	6,637	N/A
12/31/2017	30,186	1,532	N/A	6,918	N/A
9/30/2017	30,133	2,335	N/A	7,040	N/A
6/30/2017	29,832	1,931	N/A	6,910	N/A
3/31/2017	29,044	1,676	N/A	7,138	N/A
12/31/2016	27,889	912	N/A	6,497	N/A
9/30/2016	26,589	301	N/A	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A
12/31/2015	23,923	8,422	N/A	2,569	N/A
9/30/2015	23,823	9,809	N/A	3,278	N/A
6/30/2015	23,342	9,672	N/A	4,070	N/A
3/31/2015	23,015	10,177	N/A	4,619	N/A
12/31/2014	23,006	2,756	N/A	5,176	N/A
9/30/2014	23,726	4,184	N/A	5,153	N/A
6/30/2014	24,590	4,752	N/A	5,957	N/A
3/31/2014	25,647	5,143	N/A	6,902	N/A
12/31/2013	26,505	5,436	N/A	7,222	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: GSK N 'nin tahmini kazanç büyümesi (yıllık 21.9% ) tasarruf oranının ( 8.1% ) üzerindedir.

Kazançlar ve Piyasa: GSK N şirketinin kazançlarının (yıllık 21.9% ) MX pazarından (yıllık 11.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: GSK N şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: GSK N şirketinin gelirinin (yıllık 3.8% ) MX pazarından (yıllık 7.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: GSK N şirketinin gelirinin (yıllık 3.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: GSK N 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 28.7 %)

GSK Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin